Cancer Drugs & Treatments Market - Data, Analysis and Forecasts to 2023

Product code:CAN1

Availability: In stock

€2,499.00

Qty: Buy Now - OR -

'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’

 

GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. GMR Data’s latest report 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Don’t let your competitors get the head-start on you, order this report today.

 

Have you seen the recent news on Cancer Drugs?

-         Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year

-         Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes

-         EU approval for Bayer’s prostate cancer drug

-         Sanofi ditches late-stage bone marrow cancer drug

 

The Anti-cancer treatment market is already worth $77.4bn  (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development – can you afford not to be involved? Should you and your company be capturing a greater market share?

 

 

Essential facts examined in this report

1)      Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.

2)     Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.

3)     Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.

 

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.

 

Discover exactly what the industry leaders are doing TODAY -  

 

Within GMR Data’s 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.

 

Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU

 

• Rituxan

• Herceptin

• Avastin

• Gleevec

• Revlimid

• Alimta

• Velcade

 

 

PLUS – In-depth country analysis – Discover which countries and regions will drive the oncology drugs market to 2023?

 

The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.

 

But how will these country’s markets develop? This report will tell you - TODAY

 

Exclusive Industry sourced information, not available anywhere else

 

As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

 

This GMR Data report  is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug.

 

With over 240+ pages, and over 270+  charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

 

 

To order this report please contact Alice Morgan on TEL: +353 86 075 2687 or by emailing Alice.Morgan@GMRData.com

Chapter 1 Executive Summary

 

1.1 Cancer Drugs Market Review  - How will the cancer drugs market grow to 2023? What is it worth today? Why?

1.2 Chapter Breakdown

1.3 Research and Analysis Methods  - As well as the usual research tools; company fililngs, press releases, analyst knowledge, we also interviewed key decision makers / scientific researchers to gain an overall picture of the cancer drugs market.

 

 

Chapter 2 Types of Cancer;  Causes, symptoms and global prevalance of the key cancers affecting the worlds population

 

2.1 Blood Cancer Types and Symptoms

2.1.2 Blood Cancer- Global Market

2.1.3 Blood Cancer- Causes and Risk Factors

2.2 Bone Cancer Types and Symptoms

2.2.1 Bone Cancer- Global Market

2.2.2 Bone Cancer Causes and Risk Factors

 2.3 Brain Cancer Types and Symptoms

2.3.1 Brain Cancer Market- Global

2.3.2 Brain Cancer- Causes and Risk Factors

2.4 Breast Cancer Types and Symptoms

2.4.1 Breast Cancer Market- Global

2.4.2 Breast Cancer Causes and Risk factors

2.5 Digestive/ Gastrointestinal Cancer Types and Symptoms

2.5.1 Gastrointestinal Cancer Market- Global

2.5.2 Gastrointestinal Cancer- Causes and Risk Factors

2.6 Endocrine Cancers Types and Symptoms

2.6.1 Endocrine Cancer Market- Global

2.6.2 Endocrine Cancer- Causes and Risk Factors

2.7 Eye Cancer Types and Symptoms

2.7.1 Eye Cancer Market- Global

2.7.2 Eye Cancer Causes and Risk Factors

2.8 Genitourinary Cancers Types & Symptoms

2.8.1 Genitourinary Cancer Market – Global

2.8.2 Genitourinary Cancers - Causes and Risk Factors

2.9 Gynaecologic Cancers Types & Symptoms

2.9.1 Gynaecologic Cancer Market – Global

2.9.2 Gynaecologic Cancers - Causes and Risk Factors

2.10 Head & Neck Cancers Types & Symptoms

2.10.1 Head and Neck Cancer Market – Global

2.10.2 Head and Neck Cancer - Causes and Risk Factors

2.11 Respiratory/Lung Cancers Types & Symptoms

2.11.1 Respiratory Cancer Market – Global

2.11.2 Respiratory Cancer - Causes and Risk Factors 

2.12   Skin Cancers Types & Symptoms

2.12.1 Skin Cancer – Global Market

2.12.2 Skin Cancer - Causes and Risk Factors

2.13 Worldwide Cancer Facts and Statistics

2.13.1 Cancer Incidence Facts & Statistics

2.13.2 Cancer Mortality and Survival Facts & Statistics

 

Chapter 3  Cancer; Causes & Effects - Which factors effect the causes of cancers, globally.

 

3.13 Genetic Causes

3.14 Tobacco & Smoking

3.15 Physical Activities and Eating Habits

3.16 Viral Infections

3.17 Bacterial Infections

3.18 Age

3.19 Carcinogens

 

 

Chapter 4  Cancer Treatment Types  & Side Effects

 

4.1 Surgery

4.1.1 Potential Side effects of Surgery

4.2 Chemotherapy - How will the mainstay of cancer treatment fair Vs. newer types of cancer treatment?

4.2.1 Major Side effects of Chemotherapy

4.3 Radiation Therapy

4.3.1 Major Side effects of Radiation Therapy

4.4 Targeted Therapy - Precision drugs; the future or too expensive for global use?

4.4.1 Major Side effects of Targeted Therapy

4.5 Immunotherapy (Biologic Therapy) - Great potential for some cancers, but lacking the wide range of other treatments?

4.5.1 Major Side effects of Immunotherapy

4.6 Hormonal Therapy

4.6.1 Major Side effects of Hormone Therapy

4.7 Hyperthermia

4.7.1 Major Side effects of Hyperthermia

4.8 Stem Cell Transplant

4.8.1  Major Side effects of Stem Cell Transplant

4.9 Other Therapies

4.9.1 Photodynamic Therapy

4.9.2 Side effects of Photodynamic Therapy

4.9.3 Laser Treatment

4.9.4 Side effects of Laser Treatment

 

Chapter 5 Cancer Therapies / Drugs Market Forecast

 

5.1 Global Targeted Therapy Market – 2013 -2023

5.1.1 Rituxan/MabThera by Roche - Rituxan faces the end of patent exclusivity in key areas across our forecast period; how greatly will this effect global revenue?

5.1.2 Herceptin (Trastuzumab) by Roche - How will biosimilars affect Herceptin's bottom line in the near to mid future?

5.1.3 Avastin (Bevacizumab) by Roche - What potential does Avastin have to enter the combination therapies market in the US/European markets?

5.1.4 Gleevec (imatinib) by Novartis - Gleeva generated $4.7bn across 2012, how will this figure fair to 2023

5.1.5 Velcade (Bortezomib) by Takeda (Millennium) and J&J - GMR Data forecast negative growth for Velcade to 2023, how & why?

5.1.6   Tarceva (Erlotinib) by Roche - GMR Data forecast strong growth to 2018, which factors contribute to this forecast?

5.1.7    Sutent (Sunitinib) by Pfizer - Sutent revenue increased by 4% between 2011 and 2012, find out why here.

5.1.8   Sprycel (dasatinib) by Bristol Myers Squibb Sprycel's non-US sales revenue increased by 22% bewtween 2011 & 2012 ; find out which regions have driven this growth.

5.1.9 Nexavar (Sorafenib) by Bayer and Onyx - How hard will the (expected) loss of patent exclusivity hit Nexavar's bottom line across our forecast period?

5.1.10 Tasigna (Nilotinib) by Novartis - Tasigna is forecast to show strong growth throughout the forecast period - how & why?

5.1.11 Afinitor / Votubia (Everolimus) by Novartis

5.1.12 Xgeva (Denosumab) by Amgen

5.1.13 Yervoy (ipilimumab) by Bristol-Myers Squibb

5.1.14     Erbitux (cetuximab) by Bristol-Myers Squibb

5.2   Global Chemotherapy Market – 2013 -2023

5.2.1 Alimta (Pemetrexed) by Eli Lilly

5.2.2 Xeloda (capecitabine) by Roche

5.2.3 Eloxatin (oxaliplatin) by Sanofi-Aventis

5.2.4 Temodar / Temodal (temozolomide) by Merck & Co.

5.2.5 Vidaza (azacitidine) by Celgene

5.2.6 Taxotere (docetaxel) by Sanofi-Aventis

5.2.7 Treanda (bendamustine hydrochloride) by Teva Pharmaceuticals

5.3   Global Immunotherapy (Biological therapy) Market – 2013 -2023

5.3.1 Revlimid (lenalidomide) by Celgene

5.3.2 Gardasil (Human Papillomavirus Quadrivalent) by Merck

5.3.3 Zometa (zoledronate) by Novartis

5.4   Global Hormone Therapy Market – 2013 -2023

5.4.1 Faslodex (Fulvestrant) Injection by AstraZeneca

5.4.2 Zoladex (Goserelin acetate implant) by AstraZeneca

5.4.3 Arimidex (anastrozole) by AstraZeneca

5.4.4 Casodex (bicalutamide) by AstraZeneca

5.4.5 Sandostatin (octreotide acetate) by Novartis

 

  

Chapter 6 Cancer R&D Pipeline and Drugs

 

6.1 R&D Pipeline

6.1.1 Oncology Drugs; Recent Approvals

6.1.2 Late Stage Cancer Drugs

6.1.3 Key Experimental Cancer Drugs Pipeline

6.1.4 Oncology Drug Pipeline – Cancer Drugs Failures

      

 

Chapter 7 Major Trends & Challenges in the Global Cancer Drugs Market

 

7.1 Major Trends

7.1.1 Personalised Medication

7.1.2 Increasing Cancer Threat In Low & Middle Income Countries

7.1.3 Antibody Drug Conjugates (ADC)

7.1.4 Combination Therapy

7.1.5 Key Collaborations and Alliances

7.1.6 New Drug Development

7.1.7 Immunotherapy – to be the next Industry Driver

 

7.2 Major Challenges

7.2.1 Expensive Treatment

7.2.2 Biosimilars Competition

7.2.3 Generic Competition

7.2.4 Severe Side Effects of Cancer Care Treatment

7.2.5 Regulatory Hurdles in Cancer Drug Approvals

 

 

Chapter 8 Regional Landscape – The Key Global Cancer Drug Markets

 

 8.1.   The US Oncology Market to 2023 

 8.2.   The UK Oncology Market to 2023

 8.3.   France Oncology Market to 2023

 8.4   The German Oncology Market to 2023

 8.5    The Spanish Oncology Market to 2023

 8.6    The Italian Oncology Market to 2023

 8.7    The Japanese Oncology Market to 2023

 8.8    The Rest of the World Oncology Market to 2023

 

 

Chapter 9 Major Players in the Oncology Market

 

9.1 Amgen

9.2 Ariad Pharmaceutical

9.3 ASTELLAS PHARMA

9.4 AstraZeneca

9.5 Bayer healthcare pharmaceuticals

9.6 Boehringer Ingelheim

9.7 Bristol-Myers Squibb

9.8 Celgene

9.9 Eisai Co., Ltd.

9.10 Eli Lilly & Co

9.11 ImClone Systems Inc. (a subsidiary of Eli Lilly & Co)

9.12 Exelixis

9.13 GlaxoSmithKline

9.14 Merck & Co

9.15 Millennium Pharmaceuticals (Subsidiary of Takeda Oncology Company)

9.16 Novartis Pharmaceuticals

9.17 Onyx Pharmaceuticals

9.18 Pfizer Inc.

9.19 Roche

9.20 Sanofi

9.21 Teva Pharmaceuticals Industries

 

 

Chapter 10 Expert Opinion

 

10.1 Dr John Marshall, Clinical Director of Oncology, Georgetown University Hospital

10.2 Dr Anderson Ryan, Senior Group Leader at Gray Institute of Radiation, Oncology and Biology, at the University of Oxford

10.3 Dr Ben Anderson, Professor of Surgery at the University of Washington & Chair of the Breast Health Global Initiative

 

 

 

List of Tables

 

Table 2.1.1.1 Major Drugs in Blood Cancer Market

Table 2.1.2.1 Major Bone Cancer Drugs in the Market

Table 2.1.3.1 Major Brain Cancer Drugs in Market

Table 2.1.4a Breast Cancer Incidences in US & UK

Table 2.1.4b Major Breast Cancer Drugs in Market

Table 2.1.5 Major Gastrointestinal Cancer Drugs in Market

Table 2.1.6 Major Endocrine Cancer Drugs in Market

Table 2.1.7 Major Eye Cancer drugs In the Market 

Table 2.1.8 Major Genitourinary Cancers Cancer drugs In the Market 

Table 2.1.9 Major Gynaecologic Cancer drugs In the Market 

Table 2.1.10a Head & Neck Incidences in Asian Region - 2008

Table 2.1.10b Major Head and Neck Cancer Drugs in the Market

Table 2.1.11 Major Respiratory Cancer Drugs in the Market

Table 2.1.12 Major Skin Cancer Drugs in the Market

Table 4.1 Type of Cancer Surgeries

Table 4.3 Type of Radiation Therapy

Table 4.5 Types of Immunotherapy

Table 4.6 Types of Hormone Therapy

Table 4.7 Type or Ways of Hyperthermia Treatment

Table 4.8 Type of Stem Cell Transplant

Table 4.9.2 Type of Laser Treatments

Table 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012

Table 5.1.b: Global Targeted Therapy Market for Cancer Treatment: 2013-2023

Table 5.1.1.a: 2011 - 2012 Rituxan Sales Geographic Breakdown ($ bn)

Table 5.1.1.b: Rituxan Oncology Sales: 2008-2012

Table 5.1.1.c: Rituxan Sales & Forecast: 2013-2023

Table 5.1.2.a: Herceptin Sales: 2008-2012

Table 5.1.2.b: 2011 - 2012 Herceptin Sales Geographic Breakdown ($ bn)

Table 5.1.2.c: Herceptin Sales & Forecast: 2013-2023

Table 5.1.3.a: Avastin Sales: 2008-2012

Table 5.1.3.b: 2011 - 2012 Avastin Sales Geographic Breakdown ($ bn)

Table 5.1.3.c: Avastin Sales & Forecast: 2013-2023

Table 5.1.4.a: Gleevec Sales: 2008-2012

Table 5.1.4.b: 2011 - 2012 Gleevec Sales Geographic Breakdown ($ bn)

Table 5.1.4.c: Gleevec Sales & Forecast: 2013-2023

Table 5.1.5.a: Velcade Sales: 2008-2012       

Table 5.1.5.b: 2011 - 2012 Velcade Sales Geographic Breakdown ($ bn)

Table 5.1.5.c: Velcade Sales & Forecast: 2013-2023

Table 5.1.6.a: Tarceva Sales: 2008-2012

Table 5.1.6.b: 2011 - 2012 Tarceva Sales Geographic Breakdown ($/m)

Table 5.1.6.c: Tarceva Sales & Forecast: 2013-2023

Table 5.1.7.a: Sutent Sales: 2008-2012

Table 5.1.7.b: Sutent Sales & Forecast: 2013-2023

Table 5.1.8.a: Sprycel Sales: 2008-2012

Table 5.1.8.b: 2011 - 2012 Sprycel Sales Geographic Breakdown ($ m)

Table 5.1.8.c: Sprycel Sales & Forecast: 2013-2023

Table 5.1.9.a: Nexavar Sales: 2008-2012 ($/bn)

Table 5.1.9.b: Nexavar Sales & Forecast: 2013-2023

Table 5.1.10.a: Tasigna Sales: 2008-2012

Table 5.1.10.b: 2011 - 2012 Tasigna Sales Geographic Breakdown ($ m)

Table 5.1.10.c: Tasigna Sales & Forecast: 2013-2023

Table 5.1.11.a: Afinitor Sales: 2008-2012

Table 5.1.11.b: 2011 - 2012 Afinitor Sales Geographic Breakdown ($ m)

Table 5.1.11.c: Afinitor Sales & Forecast: 2013-2023

Table 5.1.12.a: Xgeva Sales: 2008-2012

Table 5.1.12.b: 2011 - 2012 Xgeva Sales Geographic Breakdown ($ m)      

Table 5.1.12.c: Xgeva Sales & Forecast: 2013-2023

Table 5.1.13.a: Yervoy Sales: 2011-2012

Table 5.1.13.b: 2011 - 2012 Yervoy Sales Geographic Breakdown ($ m)

Table 5.1.13.c: Yervoy Sales & Forecast: 2013-2023

Table 5.1.14.a: Erbitux Sales BMS: 2008-2012

Table 5.1.14.b: Erbitux Sales Merck KGaA: 2008-2012

Table 5.1.14.c: Erbitux Sales & Forecast: 2013-2023

Table 5.2.a: Global Chemotherapy Market for Cancer Treatment: 2008-2012

Table 5.2.b Market Size & Forecast – Chemotherapy Market 2013-2023

Table 5.2.1.a: Alimta Sales: 2008-2012

Table 5.2.1.b: 2011 - 2012 Alimta Sales Geographic Breakdown ($ bn)

Table 5.2.1.c: Alimta Sales & Forecast: 2013-2023

Table 5.2.2.a: Xeloda Sales: 2008-2012

Table 5.2.2.b: 2011 - 2012 Xeloda Sales Geographic Breakdown ($ m)

Table 5.2.2.c: Xeloda Sales & Forecast: 2013-2023

Table 5.2.3.a: Eloxatin Sales: 2008-2012

Table 5.2.3.b: 2011 - 2012 Eloxatin Sales Geographic Breakdown ($ bn)

Table 5.2.3.c: Eloxatin Sales & Forecast: 2013-2023

Table 5.2.4.a: Temodar Sales: 2008-2012

Table 5.2.4.b: Temodar Sales & Forecast: 2013-2023

Table 5.2.5.a: Vidaza Sales: 2008-2012

Table 5.2.5.b: Vidaza Sales & Forecast: 2013-2023

Table 5.2.6.a: Taxotere Sales: 2008-2012

Table 5.2.6.b: 2011 - 2012 Taxotere Sales Geographic Breakdown ($ bn)

Table 5.2.6.c: Taxotere Sales & Forecast: 2013-2023

Table 5.2.7.a: Treanda Sales: 2008-2012

Table 5.2.7.b: Treanda Sales & Forecast: 2013-2023

Table 5.3 Market Size & Forecast – Immunotherapy Market 2013-2023

Table 5.3.1.a: Revlimid Sales: 2008-2012

Table 5.3.1.b: Revlimid Sales & Forecast: 2013-2023

Table 5.3.2.a: Gardasil Sales: 2008-2012

Table 5.3.2.b: Gardasil Sales & Forecast: 2013-2023

Table 5.3.3.a: Zometa Sales: 2008-2012

Table 5.3.3.b: 2011 - 2012 Zometa Sales Geographic Breakdown ($/m)

Table 5.3.3.c: Zometa Sales & Forecast: 2013-2023

Table 5.3.4.a: Global Hormone Therapy Market for Cancer Treatment: 2008-2012

Table 5.3.4.b Market Size & Forecast – Hormone Therapy Market 2013-2023

Table 5.4.1.a: Faslodex Sales: 2008-2012

Table 5.4.1.b: 2011 - 2012 Faslodex Sales Geographic Breakdown ($ m)

Table 5.4.1.c: Faslodex Sales & Forecast: 2013-2023

Table 5.4.2.a: Zoladex Sales: 2008-2012

T able5.4.2.b: 2011 - 2012 Zoladex Sales Geographic Breakdown ($ m)

Table 5.4.2.c: Zoladex Sales & Forecast: 2013-2023able

Table 5.4.3.a List of generic Anastrozole manufacturing companies in 1 mg tablet type

Table 5.4.3.b: Arimidex Sales: 2008-2012

Table 5.4.3.c: 2011 - 2012 Arimidex Sales Geographic Breakdown ($ m)

Table 5.4.3.d: Arimidex Sales & Forecast: 2013-2023

Table 5.4.4.a: Casodex Sales: 2008-2012

Table 5.4.4.b: 2011 - 2012 Casodex Sales Geographic Breakdown ($ m)

Table 5.4.4.c: Casodex Sales & Forecast: 2013-2023

Table 5.4.5.a: Sandostatin Sales: 2008-2012

Table 5.4.5.b: 2011 - 2012 Sandostatin Sales Geographic Breakdown ($ m)

Table 5.4.5.c: Sandostatin Sales & Forecast: 2013-2023

Table 6.1a Oncology Drug – Recent Approvals

Table 6.1b Oncology Drug Pipeline – Top 5 Late-stage Cancer Drugs

Table 6.1c Oncology Drug Pipeline – Top 10 Experimental Cancer Drugs 

Table 6.1d Oncology Drug Pipeline – Cancer Drugs Failures  

Table 7.1 Key Emerging Countries Population Forecasts, 2013, 2018 & 2023

Table 7.2 Key Cancer Drugs Patent Expirations

Table 7.3 Revenue loss due to Generic Competition

Table 7.4 Future Revenue loss due to Generic Competition

Table 8.a:  The Global Oncology Market Forecast 2013 -2023, by Country ($ bn)

Table 8.b Key Countries CAGR 2013-2023 (%)

Table 8.c Estimated Global Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%)

Table8.d: Total Healthcare Spending and Healthcare Expenditure per Capita 2011, Sample countries ($/p/a)

Table 8.1.1: The US Oncology Market Forecast 2013-2023 ($bn)

Table 8.1.2 Estimated Rates of Cancer in the US / Survival Rate 2012

Table 8.2.1: The UK Oncology Market Forecast 2013-2023 ($bn)

Table 8.2.2: The UK’s national CDF list

Table 8.3.1: The French Oncology Market Forecast 2013-2023 ($ bn)

Table 8.4.1: The German Oncology Market Forecast 2013-2023 ($ bn)

Table 8.4.2: Germany Cancer Statistics

Table 8.5.1: The Spanish Oncology Market Forecast 2013-2023 ($ bn)

Table 8.6.1: The Italian Oncology Market Forecast 2013-2023 ($ bn)

Table 8.6.2: Percentage of patient access to oncology medicines by Italian region

Table 8.6.3: Major cancer drug prices in Italy (INCORRECT CHART BELOW)

Table 8.7.1: The Japanese Oncology Market Forecast 2013-2023 ($ bn)

Table 8.8.1: The ROW Oncology Market Forecast 2013-2023 ($ bn)

Table 8.2.2: BRIC Population, Healthcare Expenditure per Capita

Table 8.2.3 Estimated Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%)

Table 9.1.1. Amgen Oncology Product overview

Table 9.1.2. Amgen Oncology Product pipeline

Table 9.2.1 Arida Oncology Product overview

Table 9.2.2 Product pipeline

Table 9.3.1 Astellas Oncology Products Overview

Table 9.3.2 Astellas Oncology Product Pipeline

Table 9.4.1 AstraZeneca Oncology Product pipeline

Table 9.5.1 Bayer healthcare pharmaceuticals Oncology Product overview

Table 9.5.2 Bayer healthcare pharmaceuticals Oncology Product pipeline

Table 9.6.1 Boehringer Ingelheim Oncology Product overview

Table 9.6.2 Boehringer Ingelheim Oncology Product pipeline

Table 9.7.1 Bristol-Myers Squibb Oncology Products Overview

Table 9.7.2 Bristol-Myers Squibb Oncology Pipeline Projects

Table 9.8.1 Celgene oncology Product overview

Table 9.8.2 Celgene oncology Product pipeline

Table 9.9.1 Eisai Co., Ltd. Oncology Product overview

Table 9.9.2 Eisai Co., Ltd. Oncology Product pipeline

Table 9.10.1 Eli Lilly & Co oncology Products Overview

Table 9.10.2 Eli Lilly & Co oncology Pipeline Product

Table 9.11.1 ImClone Systems Inc. Oncology Product pipeline

Table 9.12.1 Exelixis Oncology Products Overview

Table 9.12.2 Exelixis Oncology Pipeline Projects

Table 9.13.1 GlaxoSmithKline Oncology Product overview

Table 9.13.2 GlaxoSmithKline Oncology Product pipeline

Table 9.13.3 GlaxoSmithKline Oncology Product Antigen-specific cancer immunotherapeutic (ASCI)

Table 9.14.1 Merck Oncology Products Overview

Table 9.14.2 Merck Oncology Merck Pipeline

Table 9.15.1 Millennium Pharmaceuticals Oncology Product overview

Table 9.15.2 Millennium Pharmaceuticals Oncology Product pipeline

Table 9.16.1 Novartis Pharmaceuticals Oncology product overview

Table 9.16.2 Novartis Pharmaceuticals Oncology Product pipeline

Table 9.17.1 Onyx Pharmaceuticals Oncology Product overview

Table 9.17.2 Onyx Pharmaceuticals Oncology Product pipeline

Table 9.18.1 Pfizer Inc. Oncology Product overview

Table 9.18.2 Pfizer Inc. Oncology Product Pipeline

Table 9.19.1 Roche Oncology Products overview

Table 9.19.2 Roche Oncology Product pipeline

Table 9.20.1 Sanofi Oncology Product overview

Table 9.20.2 Sanofi Oncology Product pipeline

Table 9.21.1 Teva Pharmaceuticals Industries Oncology Product overview

Table 9.21.2 Teva Pharmaceuticals Industries Oncology Product pipeline

 

 

 

 

List of Figures

 

Figure 2.1.1.1 Blood Cancer Type – Incidences

Figure 2.1.2.1: Global Breakdown of types of Bone Cancer

Figure2.1.11 Global Market Size as per Lung Cancer Type – Incidences

Figure 2.1.12 Global Market Size as per Skin Cancer Type – Incidences

Figure2.2.1a Global Cancer Market as per Incidences

Figure2.2.2a Global Cancer Market by Mortality & Survival

Figure 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012

Figure 5.1.b: 2012 Targeted Therapy Market by Major Drugs

Figure 5.1.c: 2012 Other Targeted Therapy Drugs Market Share

Figure 5.1d: Global Targeted Therapy Market for Cancer Treatment: 2013-2023

Figure 5.1.1.a: 2012 Rituxan Sales Geographic Breakdown

Figure 5.1.1.b: Rituxan Sales: 2008-2012

Figure 5.1.1.c: Rituxan Sales & Forecast: 2013-2023

Figure 5.1.2.1: Herceptin Sales: 2008-2012

Figure 5.1.2.2: 2012 Herceptin Sales Geographic Breakdown

Figure 5.1.2.3: Herceptin Sales & Forecast: 2013-2023

Figure 5.1.3.1: Avastin Sales: 2008-2012

Figure 5.1.3.2: 2012 Avastin Sales Geographic Breakdown

Figure 5.1.3.3: Avastin Sales & Forecast: 2013-2023

Figure 5.1.4.1: Gleevec Sales: 2008-2012</s

Actavis

Alkem Laboratories Ltd

Ambrilia Biopharma

Amgen Inc.

Ariad Pharmaceuticals

ArQule

Astellas Pharma

Astex Pharmaceuticals

AstraZeneca

Bayer

Biocon

Biogen

BioXpress

Bristol-Myers Squibb

Cadila Healthcare

Cambridge University

Cancer Research Technology Limited

Celgene

Cell Therapeutics Inc.

Celltrion

Celon Labs

Chugai

Chugai Pharmaceutical

Cipla Limited

Daiichi Sankyo Company, Limited

Debiopharm

Eisai Inc.

Eli Lilly

Fludara

Fujifilm

Fujisawa Pharmaceutical Company Ltd

Genentech

Genmab

Gilead Sciences

GlaxoSmithKline

Glenmark Pharmaceuticals Ltd

ImClone LLC

Janssen Pharmaceuticals, Inc.

Johnson & Johnson

Kyowa Hakko Kirin

Lupin Laboratories Ltd

Lyka Labs Limited

Medicare Remedies Pvt Ltd

Merck & Co., Inc.

Micromet, Inc.

Millennium Pharmaceuticals

Miracalus Pharma Pvt Ltd

Mylan

National Institute for Health and Clinical Excellence

Neon Laboratories Ltd

Newcastle University

Northern Institute for Cancer Research

Novartis

Onconova Therapeutics

Ono Pharmaceutical

Onyx Pharmaceutical

Otsuka Pharmaceuticals

Oxford BioMedica

Oxford University

Pfizer Inc.

Pharmacyclics

Plexxikon Inc.

Regeneron Pharmaceuticals

Roche

Sanofi-Aventis

Seattle Genetics

Sun Pharmaceutical Industries Ltd

SuperGen

Synthon

Taj Pharmaceuticals Ltd

Takeda

Teva Pharmaceuticals

UCLA

Yamanouchi Pharmaceutical Company Ltd

Zenyaku Kogyo Co. Ltd